Risks in the clinical applications of scopolamine butylbromide injections

To investigate and analyze the clinical application of scopolamine butylbromide injection and promote the rational use of the drug.

We classified and analyzed 3,695 cases of scopolamine butylbromide injection (effective cases only) collected over the period of January 2016 to July 2017, including details on gender, age, course of treatment, high-risk patients with other medications, adverse drug reactions, and drug combinations.

Use in high-risk patients is common, occurrence of adverse drug reaction rate in patients with high risk is 8.32 times the incidence of adverse reactions of the drug in general, in high-risk patients with adverse drug reaction the rate is 7.63 times that for lower-risk patients. Combined use of drugs is common, and there are 1.98% of cases with potential drug interactions.

The findings have importance for other Asian ethnic groups and for Chinese living outside China - Chinese are considered a "moderate-risk" ethnic group in using scopolamine butylbromide injection. We should adhere to the requirements of drug instructions, pay attention to high-risk patients, drug and drug interactions, drug and food interactions, reduce the risk of adverse drug reactions, and ensure drug safety.